Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Oct. 7, 2017 SAN DIEGO – Dr. Edsel Salvaña has two posters in the exhibit hall here, each one carrying terrible news from the Philippines, that, […]
48th Union World Conference: Sex workers and drug users with HIV in rural Kenya have high death rates from tuberculosis
Targeted and prompt TB screening and HIV treatment provision are lacking GUADALAJARA, Mexico – Despite a decrease in the numbers of TB cases reported in Kilifi, […]
Report gives evidence that neurological impacts of Zika go beyond effects on brain development By the time pediatric pathologists explored the cases reported in the August […]
Global health data review finds no country on track to end TB incidence by 2030, vast majority of countries falling short of goals to control HIV
Projections based on current burdens of disease, along with data from the preceding 26 years, show both vast inequalities of progress, as well as the likelihood […]